Institutional members access full text with Ovid®

Characterization of interleukin-33 and matrix metalloproteinase-28 in serum and their association with disease severity in patients with coronary heart disease

Liu, Cong-Lina,b,*; Shen, De-Lianga,*; Zhu, Kuia; Tang, Jun-Nana,b; Wang, Xiao-Fanga; Zhang, Lia; Zhang, Jin-Yinga

doi: 10.1097/MCA.0000000000000117
Original Research

Objective: To investigate serum levels of interleukin (IL)-33 and matrix metalloproteinase-28 (MMP-28) in patients with coronary heart disease (CHD) and to evaluate their association with disease severity.

Methods: A total of 103 patients with CHD, including 27 cases of acute myocardial infarction (AMI), 33 cases of unstable angina pectoris (UAP) and 43 cases of stable angina pectoris were enrolled to detect serum levels of IL-33 and MMP-28 by enzyme-linked immunosorbent assays. Forty volunteers without CHD served as the control group.

Results: Compared with stable angina pectoris and control groups, serum levels of IL-33 were significantly lower (P<0.01) and serum concentrations of MMP-28 were higher (P<0.05) in AMI and UAP groups. Serum levels of IL-33 in single-vessel, double-vessel and triple-vessel lesion groups were lower than that in the control group (P<0.05), and the differences among the three groups were not significant (P>0.05), whereas only levels of MMP-28 in double-vessel and triple-vessel lesion groups were higher than in the control group (P<0.05). Spearman’s correlation analyses showed a negative correlation between serum levels of IL-33 and MMP-28 in AMI and UAP groups (r=−0.596, P<0.05 and r=−0.750, P<0.01). A binary logistic regression analysis showed that IL-33, low-density lipoprotein cholesterol, and MMP-28 may be independent predictors of the occurrence of acute coronary syndrome.

Conclusion: A decreased level of IL-33 and an elevated concentration of MMP-28 were found in CHD patients and correlated with disease severity. IL-33 and MMP-28 may play important roles in the development of CHD or as markers of disease severity.

aDepartment of Cardiology

bInstitute of Clinical Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China

* Cong-Lin Liu and De-Liang Shen contributed equally to the writing of this article.

Correspondence to Jin-Ying Zhang, MD, PhD, Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, People’s Republic of China Tel: +86 135 038 30283; fax: +86 0371 67967641; e-mail: jyzhang@zzu.edu.cn

Received January 5, 2014

Received in revised form January 29, 2014

Accepted March 2, 2014

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins